Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin

Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin

Any other malignancy diagnosed within  year of study entry (except basal or squamous cell skin cancers or noninvasive cancer of the cervix) is excluded

Patients with active malignancies other than NSCLC or prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers

Evidence of metastatic disease or other malignancy (except squamous or basal cell skin cancers)

Malignancy other than lymphoma, unless () in complete remission and more than  years from last treatment, or () cervical/anal squamous cell carcinoma in situ or () superficial basal cell and squamous cell cancers of the skin

Subjects on chronic immunosuppression, or who have a history of compromised immune function (e.g. history of or current malignancy other than BCC/squamous cell skin cancers)

Previous or concurrent cancers other than basal or squamous cell skin cancers or superficial bladder cancer unless disease free for at least  years

Concurrent malignancy (excluding basal and squamous cell skin cancers).

Other current malignancy (except squamous or basal cell skin cancers)

Concurrent active malignancy, with the exception of early stage basal cell or squamous cell skin cancer

Patients with active malignancies other than SCLC or patients with prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers

Malignancy other than lymphoma, unless () in complete remission and more than  years from last treatment, or () cervical/anal squamous cell carcinoma in situ or () superficial basal cell and squamous cell cancers of the skin

Patients with active malignancies other than NSCLC or prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers

Previous or concurrent cancers other than basal or squamous cell skin cancers or superficial bladder cancer unless disease free for at least  years

History of other cancer, excluding squamous cell and basal cell skin cancers =<  years prior to registration

Curatively treated basal cell/squamous cell skin cancer

Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin

Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin

Prior cancers <  years, with the exception of in-situ cervical cancer, low grade prostate cancer and basal or squamous cell skin cancers

Patients that have concurrent malignancies (except localized basal cell or squamous cell skin cancers)

Concurrent malignancy (excluding basal and squamous cell skin cancers)

Evidence of metastatic disease or other malignancy (except squamous or basal cell skin cancers).

Be free of any recurrence of cancer; and have no other cancers within five years of enrollment except for basal cell or squamous cell tumors of the skin that have been surgically excised

Multiple cancers except basal cell carcinoma

Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin

Patients with active malignancies other than NSCLC or prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers

Curatively treated basal cell or squamous cell skin cancer